In 2022–23, only 67% of eligible adults in England completed their bowel cancer screening, down from 72% five years earlier. The NHS England target of 75% remains unmet, and the gap between the richest and poorest quintiles has widened to 12 percentage points. Behind these numbers lies a more troubling story: patients who do return their faecal immunochemical test (FIT) often face months-long waits for a follow-up colonoscopy. As delays lengthen, participation drops further, creating a cycle that undermines the very purpose of screening.

A Silent Drop in Participation

Bowel cancer screening in England relies on the FIT, a simple kit that detects hidden blood in stool. Eligible adults aged 60–74 receive a kit every two years. When uptake falls, cancers are missed. The decline from 72% to 67% may appear modest, but in absolute numbers it means hundreds of thousands of people skipped screening. Disparities are stark: in the most deprived fifth of the population, uptake hovers around 58%, compared with 70% in the least deprived, according to NHS Digital data.

Primary care staff have noticed the trend. “We used to see a steady stream of patients bringing in their kits,” says Dr. Helen Carter, a GP in Manchester. “Now many tell us they never posted it back. Some say they forgot, but others mention hearing about long waits for colonoscopy and deciding it was not worth the anxiety.” The NHS England target of 75% was set a decade ago and has never been met. The pandemic dealt a heavy blow, but recovery has been uneven.

Public Health England surveys suggest that awareness of screening benefits remains high, but practical barriers—fear of the procedure, lack of time, language difficulties—have grown more pronounced. The drop is not uniform: some regions, like London, have seen uptake fall below 60%, while parts of the South West approach 72%. The reasons are multifactorial, but the lengthening colonoscopy queue is a common thread.

Another contributing factor is the variation in how GP practices promote screening. A 2023 audit by the British Society of Gastroenterology found that practices with a dedicated screening champion had uptake rates roughly 8–10% higher than those without. Yet fewer than one in five practices have such a role. This suggests that local engagement, not just national policy, plays a crucial role in encouraging participation.

The Colonoscopy Bottleneck

Colonoscopy is the gold-standard follow-up after a positive FIT result. Yet median wait times in many NHS trusts now exceed six weeks, and Cancer Research UK reports that one in ten patients waits over three months. The backlog, worsened by COVID-19 and staffing shortages, leaves patients in limbo. NHS diagnostic capacity remains roughly 15% below pre-pandemic levels, according to the Royal College of Physicians.

For patients like 68-year-old retired teacher Susan Mitchell, the wait was excruciating. “My FIT came back positive in March 2023. My GP said I’d be seen within a month. I waited eleven weeks. Every day I wondered if the cancer was growing.” Fortunately, her colonoscopy showed only benign polyps, but the experience left her reluctant to screen again. “If I get another kit, I might bin it. I can’t go through that anxiety again,” she says.

The bottleneck stems from a shortage of endoscopists and equipment. The NHS has trained more endoscopy nurses and introduced robotic systems to speed procedures, but demand continues to outstrip supply. Some trusts have adopted a “straight-to-test” pathway, bypassing outpatient appointments, but capacity constraints limit its reach. Meanwhile, the number of positive FIT results has risen as the test becomes more sensitive, adding pressure.

Another factor is the ageing of the eligible population. As more people enter the 60–74 age bracket, the total number of screening kits issued grows each year. According to NHS England, the number of eligible adults increased by roughly 1–2% annually, compounding the demand for colonoscopy. Without a proportional increase in endoscopy capacity, wait times will continue to stretch.

Some trusts have tried innovative solutions, such as using general practitioners with a special interest in endoscopy to perform procedures. However, training and accreditation remain barriers. A 2024 report from the Health Foundation estimated that closing the capacity gap would require an additional 500 endoscopists nationwide, a target that current training pipelines cannot meet within the next three years.

How Delays Deter Participation

Qualitative research published in BMJ Open in 2023 found that anxiety about waiting for colonoscopy is a significant deterrent. Patients who hear stories of long delays may decide not to return their FIT kit at all. The study’s authors noted that “the anticipated wait amplifies the psychological burden of screening, reducing willingness to engage.” Primary care staff report a growing number of patients declining referral outright after a positive FIT, preferring to “wait and see.”

The public largely misunderstands that most abnormal FIT results are not cancer. Roughly 90% of positive tests turn out to be false alarms—caused by haemorrhoids, polyps, or other benign conditions. Yet the message has not penetrated. “People hear ‘positive’ and think ‘cancer,’” says Dr. Carter. “Then they hear about the wait and decide ignorance is better.” This is a tragic irony: the screening programme saves lives, but its own success in detecting abnormalities now fuels avoidance.

Health psychologists argue that the NHS must reframe the narrative. Rather than emphasising the risk of cancer, campaigns should stress that most positive results are harmless and that a timely colonoscopy provides reassurance. Without such messaging, the cycle of delay and deterrence will persist.

There is also a practical dimension: patients who delay or decline colonoscopy after a positive FIT may later present with symptoms at a more advanced stage. A 2022 analysis by Cancer Research UK estimated that each month of diagnostic delay increases the risk of progression from early to late-stage disease by roughly 2–3%. For a cancer that is highly treatable when caught early, the consequences of avoidance are severe.

Counter-arguments exist, however. Some clinicians argue that the 90% false-positive rate means the system is appropriately cautious, and that the focus should be on reassuring patients rather than speeding up an already strained service. Others point out that the psychological distress of waiting is real but that prioritising symptomatic patients over screening follow-ups may be a more ethical allocation of resources. These tensions highlight the complexity of the trade-offs involved.

The FIT Test: Simple Kit, Complex Barriers

The faecal immunochemical test is deceptively simple: a small plastic stick, a sample tube, a prepaid envelope. Yet barriers to completion are many. Language and health literacy issues reduce kit return among ethnic minorities and recent immigrants. A 2022 study in The Lancet Public Health found that people whose first language is not English were 30% less likely to return their kit. Instructions, despite pictograms, can be confusing.

England’s FIT cut-off is set at 120 µg haemoglobin per gram of faeces. Lowering the threshold would detect more early-stage cancers but would also overwhelm colonoscopy services with false positives. Scotland uses a lower cut-off of 80 µg/g, and some experts argue England should follow suit—but only after capacity improves. “We are caught in a trade-off,” says Professor James Evans, a health economist at the University of York. “A lower threshold saves lives, but only if we can scope everyone promptly. Right now, we cannot.”

Other barriers include forgetfulness, disgust with handling stool, and lack of a convenient place to post the kit. Some GP practices now offer drop-off points, but uptake varies. The NHS has piloted text reminders and phone calls, which boost return rates by 8–12%, but these interventions are not yet universal.

Cultural factors also play a role. In some communities, discussing bowel function is taboo, making the kit feel embarrassing. A 2023 qualitative study from the University of Birmingham found that South Asian women in particular reported discomfort with the test, partly due to modesty concerns. Tailored community engagement, such as female health ambassadors, has been suggested but remains rare.

A further barrier is the physical design of the kit itself. Patients with arthritis or poor eyesight may struggle to manipulate the small tube and stick. A 2024 usability study by the University of Leeds found that roughly 8% of older adults could not complete the test correctly on their first attempt due to dexterity issues. Redesigning the kit with larger components and clearer colour-coding could improve accessibility, but such changes have not yet been implemented.

What Other Countries Do Differently

Scotland offers a direct-access colonoscopy within 14 days for patients with a positive FIT. The guarantee, introduced in 2021, has helped maintain screening uptake above 70%. “Knowing you’ll be seen quickly is a powerful motivator,” says Dr. Fiona MacLeod, a public health consultant in Edinburgh. “It reduces the anxiety that drives avoidance.” However, Scotland’s approach required a 20% increase in endoscopy capacity and a centralised booking system, which took years to implement. Critics note that the guarantee may not be sustainable if demand continues to rise.

Denmark uses an integrated IT system that automatically flags overdue patients and sends reminders. GPs are notified if a patient has not returned a kit within six weeks, prompting a phone call. The result: uptake consistently above 75%. Australia mails repeat kits annually with prepaid return envelopes and a simple one-step process. Japan relies on primary care gatekeeping: patients receive their FIT kit from a GP, who can triage and schedule colonoscopy directly, reducing waits.

Each system has its own trade-offs. Scotland’s guarantee requires significant investment in endoscopy capacity. Denmark’s IT system demands robust data sharing. But the common thread is that reducing the time between positive FIT and colonoscopy boosts participation. England could learn from these models, though adaptation would take years.

Another model comes from Finland, where screening is organised through municipal health centres and colonoscopy capacity is aligned with screening volumes from the outset. Uptake there exceeds 80%, and wait times for colonoscopy average under three weeks. The Finnish system benefits from a smaller population and a strong primary care infrastructure, but its principles—early capacity planning, integrated IT, and GP involvement—are transferable.

Some critics warn against direct comparisons, noting that the UK’s larger and more diverse population makes implementation harder. For instance, Scotland’s 14-day guarantee works partly because its population is roughly one-tenth of England’s. Scaling such a guarantee to England would require proportionally larger investments and a more complex logistical system. Nevertheless, the principles of prompt follow-up and patient-centred communication remain universally valid.

GP Practices as the Missing Link

Only 40% of GP practices proactively call non-responders to screening, according to a 2023 survey by the Royal College of GPs. Text reminders boost uptake by 8–12% in pilot studies, but many practices lack the staff to implement them. Practice-level data on screening status is rarely shared with clinicians during consultations, so opportunities to encourage participation are missed.

Time pressure is a major barrier. A typical GP appointment lasts ten minutes, leaving little room for preventive discussions. “I know I should ask every patient over 60 about their screening kit,” says Dr. Carter. “But when I have a queue of people with chest pain, rashes, and medication reviews, it often slips my mind.” Some practices have trained healthcare assistants to check screening status during routine checks, but this is not standard.

Community outreach, such as pop-up screening events in supermarkets or community centres, has shown promise in deprived areas. A pilot in East London increased uptake by 15% among non-responders. But such programmes are resource-intensive and not yet scaled. Without a systematic approach, the missing link remains the GP practice.

One innovative approach is the use of social prescribing link workers. In a trial in Yorkshire, link workers contacted non-responders by phone, explained the kit, and offered to post a new one. Uptake in the intervention group rose by 18% compared with controls. However, scaling this would require training and funding for link workers, which is not currently budgeted.

Another promising strategy is the use of electronic health record prompts. A study in the British Journal of General Practice found that when GPs received an automatic alert during consultations for patients overdue for screening, the odds of a discussion increased by roughly 40%. Yet fewer than one in three practices have such alerts enabled. Integrating screening status into routine clinical workflows could be a low-cost, high-impact intervention.

Steps to Reverse the Trend

Reversing the decline requires investment in colonoscopy capacity: more training slots for endoscopists, robotic units to speed procedures, and extended hours. The NHS Long Term Plan pledged to expand diagnostic capacity, but progress has been slow. A public campaign to normalise FIT completion despite wait times could help, but it must be honest about the delays while emphasising that most positives are benign.

Adopting Scotland’s 14-day referral guarantee across England would be a bold step, but it would require significant funding and workforce planning. Funded GP outreach to the lowest-participation quintile—including text reminders, phone calls, and home visits—could close the equity gap. Some experts advocate lowering the FIT threshold gradually as capacity improves, balancing sensitivity and feasibility.

Another policy option is to extend the screening age range. Currently, England screens ages 60–74, but bowel cancer incidence rises sharply after 50. A 2023 modelling study from the University of Sheffield suggested that lowering the starting age to 50 would detect around 15% more cancers, but would also increase colonoscopy demand by roughly 25–30%. Until capacity expands, such an extension is unlikely.

None of these steps is a silver bullet. The system faces competing pressures: rising demand, workforce shortages, and budget constraints. But the cost of inaction is measured in avoidable deaths. Bowel cancer is the second deadliest cancer in the UK, and screening can catch it early. The challenge is not just to offer the test, but to ensure that the pathway from kit to colonoscopy is swift enough that patients trust it.

As Dr. Carter puts it: “We need to show patients that the system works. If they do the test, they won’t be left waiting. That trust has eroded, and rebuilding it will take more than leaflets—it will take shorter queues.”

Ultimately, the solution lies in a combination of increased capacity, better communication, and targeted outreach. While no single intervention can fix the problem overnight, a coordinated effort across primary care, secondary care, and public health could begin to reverse the downward trend. The alternative—accepting lower uptake and more late-stage diagnoses—is a cost that the NHS, and its patients, cannot afford.

This article is for informational purposes only and does not constitute personalised medical advice. Readers should consult their GP regarding their individual screening needs.